Sort by
41 - 60 of 7654
PDF
Coordinating Parenting Time and Child Support: Experiences and Lessons Learned From Three States
Child-Support-Parenting-Time-Brief.pdf
ASPE Research Subject to Institutional Review Board Exemption
The Common Rule governing Human Subjects Protection allows exemptions to IRB requirements for research that is:
How to Include Social Capital in a Human Services Program Logic Model
This tool demonstrates how human services practitioners can use a logic model to map out the role social capital plays in their programs, providing hypothetical examples and a blank tool for practitioners to fill in themselves.
Proposal Submissions: Physician-Focused Payment Model Technical Advisory Committee
PTAC
Members
Meetings
FAQs
Resources
Requests for Correction
CDC - OSQ submission 1-7-20.pdf
Fries RFC Pt Centered Care Advocacy Grp Jan 14 20.pdf
Part D Gross Drug Costs Graph - Text Version
Part D Gross Drug Costs, 2016, $US Billions
MultiSource: $42.7
Brands: $8.7
Savings: $
Single souce: $102.0
Generics: $34.0
Spending if fully substituted: $5.9
Return to the Generic and Biosimilars page .
Medicare Part B Drug Spending
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Medicare Part B Drugs: Pricing and Incentives
Research
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Prescription Drug Pricing: ASPE Resources Related to Safe Harbor Rule
Chart: Price Changes by Product - Text Version
Chart: Price Changes by Product, Post Blueprint Period in 2017 Compared to the Same Time Period in 2018
Prescription Drugs: Flowchart Text Version
Pharmaceutical supply chain includes 6 parties: payers, consumers, pharmacies, pharmacy benefits manager, distributor, and drug manufacturer.
Incentivizing Generic and Biosimilar Product Uptake
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Prescription Drugs
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
Prescription Drug Pricing Reports to Congress
Home
Generics and Biosimilars
Reports to Congress
Medicare Part B
Research
National Action Plan for Combating Antibiotic-Resistant Bacteria Progress Report: Year 4
Antibiotic Resistance continues to pose a significant threat to our Nation’s public health. To coordinate and enhance the public health response to this threat, the U.S. Government developed the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB). The CARB Task Force is co-chaired by HHS, USDA, and DOD. This report describes
Progress-Report-Year-4-CARB-National-Action-Plan-Final.pdf
Individuals' Awareness of a Dementia Diagnosis Issue Brief
Individuals' Awareness of a Dementia Diagnosis Issue Brief
Sarita L. Karon, PhD; Emily Graf, BA; Natalie Mulmule, BS; and Stephanie Hughes, MPP
RTI International
January 2020
Printer Friendly Version in PDF Format (5 PDF pages)
Implications of Alternative Methods of Identifying Populations with Dementia Issue Brief
Implications of Alternative Methods of Identifying Populations with Dementia Issue Brief
Sarita L. Karon, PhD; Emily Graf, BA; Natalie Mulmule, BS; and Heather Menne, PhD
RTI International
January 2020
Printer Friendly Version in PDF Format (5 PDF pages)
Individuals' Awareness of a Dementia Diagnosis Issue Brief
This study examined the characteristics of people who do not report having a diagnosis of dementia, despite a documented diagnosis by a health care provider, to health understand the factors that may contributed to their lack of awareness or failure to report. Understanding these factors is a key to taking steps to increasing awareness.
DemAwareIB.pdf
Implications of Alternative Methods of Identifying Populations with Dementia Issue Brief
This study sought to identify the amount of overlap among three methods of identifying people with dementia, and to obtain national estimates of the number of people with dementia. It also explored key characteristics of people identified as having dementia by the various methods, to understand potential causes and implications of differences for
DemAlterIB.pdf
